Interestingly, Baldassari et al. (2018) demonstrated that a combined treatment with miRNAs, including miR-9-5p, enhances the activity of specific anti-BC drugs in vitro, even on the most aggressive HER2+ and TNBC subtype. The gene discussed is ERBB2; the disease is breast cancer.